| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ping An Biomedical Co., Ltd. Ordinary Shares$0.17
0 (-2.76%)
Market Cap
3.71 M
EPS
-
P/E Ratio
-
Value Trade
119.51 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
72.35 K
52 Week Range
0.12 - 1.22
% held by Insiders
-
% held by Institutions
-
Enterprise Value
-
Total Shares
20.48 M
Short %
0.45 %
Float Shares
9.13 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PASW
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Ping An Biomedical Co., Ltd. Ordinary Shares (PASW) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PASW
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PASW
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PASW
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PASW Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PASW Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PASW
Mar 19, 2026All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital Hong Kong
Ping An Biomedical Co., Ltd. successfully passed all five resolutions at its 2026 Annual General Meeting, allowing for a significant overhaul of the company's share capital structure. This includes the introduction of high-vote Class B shares and a targeted share exchange with INSPIRETECH LTD. The changes also encompass a large-scale share consolidation and amendments to the company's memorandum and articles of association. The resolutions received strong support from shareholders, suggesting a positive outlook for the company's strategic direction.
Read more →-PASW
Mar 9, 2026Ping An Biomedical Co., Ltd. 22/F, China United Plaza, 1002-1008, Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of
Ping An Biomedical Co., Ltd. has announced its upcoming Annual General Meeting (AGM) scheduled for March 18, 2026. The meeting will include key proposals such as amendments to the company's authorized share capital and the adoption of a new memorandum of association. Shareholders of record as of March 3, 2026, will be entitled to vote on these matters. The company encourages all shareholders to participate by voting via various methods provided in the proxy statement.
Read more →-PASW
Jan 9, 2026Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation Hong Kong
Ping An Biomedical Co., Ltd. has successfully secured a strategic investment from several notable industry figures, including Yao Jinbo of 58 Group, Wang Donghui of Amiba Capital, and Li Daxue of Magcloud Group. This investment is anticipated to enhance the company's biopharmaceutical research and development, as well as its technological implementation capabilities. Management emphasized the importance of these partnerships in driving growth and innovation within the healthcare sector. The strategic move signals strong confidence in the company’s future prospects and market positioning.
Read more →-PASW
Nov 28, 2025Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter Hong Kong
Ping An Biomedical Co., Ltd. has received a deficiency letter from Nasdaq, indicating that its closing bid price has fallen below the required minimum of $1 per share. The company has a compliance period of 180 days, until May 25, 2026, to rectify this issue. If compliance is not achieved, the company may face delisting, although there remains a possibility of an extension under certain conditions. The company is currently assessing its options to regain compliance, but no guarantees are provided.
Read more →-PASW
Sep 29, 2025MAJESTIC IDEAL HOLDINGS LTD INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS For the Six Months Ended
Majestic Ideal Holdings Ltd has released its unaudited condensed consolidated financial statements for the six months ending March 31, 2024 and 2025. The financials reveal a substantial net loss of RMB 4,233,119 for the period ending in 2025, marking a decline from the previous year's profit. Additionally, there is a concerning increase in the shareholders' deficit, which has risen from RMB 7,188,181 to RMB 11,746,188. The company's current liabilities continue to surpass its current assets, posing potential liquidity challenges.
Read more →-PASW
Sep 12, 2025Majestic Ideal Holdings Ltd Announces Approval of Name Change to "Ping An Biomedical Co., Ltd." at Extraordinary General Meeting Hong Kong
Majestic Ideal Holdings Ltd. announced the approval of its name change to Ping An Biomedical Co., Ltd. during an Extraordinary General Meeting of Shareholders held in Hong Kong. The change is subject to the approval of the Registrar of Companies in the Cayman Islands and aims to better reflect the company’s focus on biomedical and healthcare technologies. A majority of shareholders approved the special resolution for the name change, which is expected to enhance the company's corporate image and market position.
Read more →-PASW
Sep 3, 2025Majestic Ideal Holdings Ltd 22/F, China United Plaza, 1002-1008, Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong PROXY STATEMENT AND NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To the shareholders of
Majestic Ideal Holdings Ltd is set to hold an Extraordinary General Meeting on September 12, 2025, at their office in Kowloon, Hong Kong. Shareholders are invited to discuss and vote on proposals that include a name change to Ping An Biomedical Co., Ltd., pending regulatory approval. The meeting reflects the company's commitment to shareholder engagement and transparency, with provisions for both in-person attendance and proxy voting. All ordinary shareholders as of August 22, 2025, are eligible to participate.
Read more →-PASW
Jul 16, 2025Majestic Ideal Holdings Ltd Statement of Policy Concerning Trading in Company Securities Adopted
Majestic Ideal Holdings Ltd has adopted a comprehensive Statement of Policy concerning the trading of company securities. This policy applies to all employees, officers, and directors, emphasizing compliance with applicable laws and regulations. The document outlines the use of inside information, responsibilities regarding trading practices, and consequences for insider trading violations. The company aims to ensure fairness in securities transactions and enhance transparency for shareholders.
Read more →Competitive Position
How PASW ranks across every disease it competes inCompetitive Position is a premium feature
See how PASW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial